Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02678286 · ClinicalTrials.gov registry record · Phase 3
Evaluation of N1539 Following Abdominoplasty Surgery
A Phase 3 study, sponsored by Baudax Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 219
- Enrollment target
NCT02678286 is a Phase 3 study that has completed, run by Baudax Bio. The registered enrollment target is 219 participants.
The verdict
NCT02678286, a Phase 3 study, has completed, sponsored by Baudax Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 219 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the analgesic efficacy of N1539 in subjects with acute moderate to severe pain following abdominoplasty surgery.
Interventions
- DRUG Intravenous Placebo
- DRUG N1539
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02678286
The ClinicalTrials.gov registry entry for NCT02678286 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baudax Bio, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intravenous Placebo is the first listed.
NCT02678286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02678286 about?
NCT02678286 is a clinical study titled "Evaluation of N1539 Following Abdominoplasty Surgery". The primary objective of this study is to evaluate the analgesic efficacy of N1539 in subjects with acute moderate to severe pain following abdominoplasty surgery.
What is the current status of trial NCT02678286?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 219 participants. The study started on 2016-01. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02678286?
The interventions under investigation include: Intravenous Placebo (DRUG), N1539 (DRUG).
Who is sponsoring clinical trial NCT02678286?
This trial is sponsored by Baudax Bio, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.